These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia. Petrović V; Vuković V; Patić A; Marković M; Ristić M PLoS One; 2022; 17(2):e0263468. PubMed ID: 35108321 [TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang H; Wang W; Zhang W; Li N; Xie Z; Ding L; You W; Zhao Y; Yang X; Liu Y; Wang Q; Huang L; Yang Y; Xu G; Luo B; Wang W; Liu P; Guo W; Yang X Lancet Infect Dis; 2021 Jan; 21(1):39-51. PubMed ID: 33069281 [TBL] [Abstract][Full Text] [Related]
28. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial. Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265 [TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 immunogenicity at the crossroads. Karamloo F; König R Allergy; 2020 Jul; 75(7):1822-1824. PubMed ID: 32401346 [No Abstract] [Full Text] [Related]
30. Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study. Wang X; Deng Y; Zhao L; Wang L; Fu Z; Tang L; Ye F; Liu Q; Wang W; Wang S; Hu B; Guan X; Han Z; Tong Y; Rodewald LE; Yin Z; Tan W; Wang F; Huang B Vaccine; 2022 Sep; 40(39):5701-5708. PubMed ID: 36031501 [TBL] [Abstract][Full Text] [Related]
31. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development. Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK Front Immunol; 2020; 11():1880. PubMed ID: 32973779 [TBL] [Abstract][Full Text] [Related]
32. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. Gupta T; Gupta SK Int Immunopharmacol; 2020 Sep; 86():106717. PubMed ID: 32585611 [TBL] [Abstract][Full Text] [Related]
34. Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development. Khalaj-Hedayati A J Immunol Res; 2020; 2020():7201752. PubMed ID: 32695833 [TBL] [Abstract][Full Text] [Related]
35. Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2. Badano MN; Sabbione F; Keitelman I; Pereson M; Aloisi N; Colado A; Ramos MV; Ortiz Wilczyñski JM; Pozner RG; Castillo L; Wigdorovitz G; E de Bracco MM; Fink S; Chuit R; Baré P Mol Immunol; 2022 Mar; 143():94-99. PubMed ID: 35091231 [TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. Qin E; Shi H; Tang L; Wang C; Chang G; Ding Z; Zhao K; Wang J; Chen Z; Yu M; Si B; Liu J; Wu D; Cheng X; Yang B; Peng W; Meng Q; Liu B; Han W; Yin X; Duan H; Zhan D; Tian L; Li S; Wu J; Tan G; Li Y; Li Y; Liu Y; Liu H; Lv F; Zhang Y; Kong X; Fan B; Jiang T; Xu S; Wang X; Li C; Wu X; Deng Y; Zhao M; Zhu Q Vaccine; 2006 Feb; 24(7):1028-34. PubMed ID: 16388880 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]